Mizagliflozin is primarily used in the treatment of type 2 diabetes mellitus. It functions as a sodium-glucose co-transporter 1 (SGLT1) inhibitor, which helps to reduce the absorption of glucose in the intestines. This action leads to lower blood glucose levels, making it an effective option for managing diabetes. Additionally, Mizagliflozin has shown potential in improving glycemic control without significantly increasing the risk of hypoglycemia. It is often considered for patients who may not respond adequately to other antidiabetic medications. The drug’s ability to target intestinal glucose absorption also makes it a unique therapeutic option in the diabetes treatment landscape.